Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Glanzmann's thrombasthenia future or investigational therapies
Introduction
Overview
Overview
Gene therapy is a cutting the edge method for treatment of various diseases. Gene therapy in animal models demonstrates good potential of this treatment for curing patients with Glanzmann’s thrombasthenia. As an example for targeting transgene expression in the developing megakaryocytes from two patients with GT in vitro, αIIbβ3 promoter was expressed on these transduced megakaryocytes. CD34+ cells was demonstrated utilizing mice leukemia retrovirus vectors, by this method the Glanzmann’s thrombasthenia was corrected.[1]
Future or Investigational Therapy
Future or Investigational Therapy
Gene therapy has a significant potential for curing Glanzmann’s thrombasthenia in the near future.[2]
References
References
- ↑ Blickstein D, Dardik R, Rosenthal E, Lahav J, Molad Y, Inbal A (2014). “Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies”. Isr Med Assoc J. 16 (5): 307–10. PMID 24979837.
- ↑ Solh T, Botsford A, Solh M (2015). “Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options”. J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]